CHEVRIER, MARC,FRIEMUTH, WILLIAM,ZHONG, ZHENSHAO,ODENHEIMER, DANIEL,PERKINS, MELISSA D
申请号：
NZ56820406
公开号：
NZ568204A
申请日:
2006.10.05
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of an antagonist of Neutrokine-alpha for the preparation of a pharmaceutical composition for treating a patient with systemic lupus erythematosus wherein the patient has an ANA titer ? 1 :80 or ? 30 IU/mL of anti-dsDNA antibodies in their blood plasma or serum and wherein the antagonist of Neutrokine-alpha is selected from the group consisting of: (i) an anti-Neutrokine-alpha antibody； (ii) a protein comprising the Neutrokine-alpha binding domain of TACI (SEQ ID NO:6)； (iii) a protein comprising the Neutrokine-alpha binding domain of BCMA (SEQ ID NO:8)； (iv) a protein comprising the Neutrokine-alpha binding domain of BAFF-R (SEQ ID NO:10)； (v) a protein comprising a variant of the BAFF-R Neutrokine-alpha binding domain having the amino acid sequence of amino acid residues 2-70 of SEQ ID NO:26； (vi) a Neutrokine-alpha-binding peptide or polypeptide； (vii) a peptibody； (viii) a Neutrokine-alpha protein variant； and (ix) an anti-Neutrokine-alpha receptor antibody.
